1. Search Result
Search Result
Pathways Recommended: Neuronal Signaling JAK/STAT Signaling
Results for "

ST2/IL-33 signaling

" in MedChemExpress (MCE) Product Catalog:

4

Inhibitors & Agonists

2

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99444
    Astegolimab
    2 Publications Verification

    MSTT 1041A; RG 6149

    Interleukin Related MDM-2/p53 NF-κB Cardiovascular Disease Inflammation/Immunology
    Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody. Astegolimab blocks IL-33 signaling by targeting the IL-33 receptor ST2. Astegolimab reduces p53 expression, mitigates IL33-upregulated SASP factors such as IL1α, IL6 and MCP1. Astegolimab mitigates IL33-increased p-p65/p65 ratio. Astegolimab blocks CM-induced neutrophil extracellular trap (NET) formation. Astegolimab is used in chronic obstructive pulmonary disease (COPD) and myocardial research .
    Astegolimab
  • HY-168532

    Interleukin Related Inflammation/Immunology
    ST2-IN-1 is a ST2 inhibitor. ST2-IN-1 blocks the binding interaction between ST2 and IL-33, thereby attenuating the downstream ST2/IL-33 signaling pathway. ST2-IN-1 reduces IL-1β release from mast cells and alleviates ST2 upregulation in cells. ST2-IN-1 can be used for research on inflammatory and immune-related diseases .
    ST2-IN-1
  • HY-P991633

    Interleukin Related Inflammation/Immunology
    TQC2938 is a humanized IgG2 monoclonal antibody inhibitor targeting Stimulation-2 (ST2). TQC2938 inhibits the ST2/IL-33 signaling pathway, reduces the level of downstream Th2 cytokines (such as IL-4, IL-5, and IL-13) and eosinophils as well as other inflammatory cells. TQC2938 can be used for inflammatory diseases like asthma research .
    TQC2938
  • HY-W060417

    Interleukin Related Inflammation/Immunology Cancer
    iST2-1 is an Stimulation-2 (ST2) inhibitor with an IC50 value of 46.65 μM, blocks interaction between ST2 and IL-33, inhibits downstream signaling. iST2-1 functions as an immunomodulator, reduces proliferation of CD4 + and CD8 + T cells, increases regulatory T cell populations, reduces IFN-γ +CD4 + T cell populations, increases Foxp3 +CD4 + regulatory T cell populations in the gastrointestinal tract. iST2-1 reduces plasma soluble ST2 and IFN-γ levels, reduces graft-versus-host disease scores, improves survival in graft-versus-host disease animal models, preserves graft-versus-tumor effect. iST2-1 can be used for the research of graft-versus-host disease .
    iST2-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: